



## MitraClip Therapy Clinical Evidence & Trial Program

Victoria Delgado, MD, PhD Leiden University Medical Center






## EUrovalve March 27 - 28, 2015

#### **Faculty disclosure**

Victoria Delgado

I disclose the following financial relationships:

Paid speaker for Abbott Vascular



www.eurovalvecongress.com

#### Why to treat MR?

Mitral regurgitation: the second most

frequent valvular heart disease

- Associated with heart failure
- Increasing economic burden

#### Prevalence of MR and treatment

19,868 patients with primary or secondary MR 2009-2010

4099 undergoing surgical MV repair/replacement

62% male

65±14 years

15% Heart failure

15,769 medical treatment

53% male

76±10 years

62% Heart failure

Trochu et al. Arch Cardiovasc Dis 2015

#### **Derived costs**

	Surgical t (N=4		Medical treatment (N=15,769)		
	Repair (N=2567)	Replacement (N=1532)	Heart failure (N=9774)	No-HF (N=5995)	
Length of stay (days)	15 ± 12.5	12.1 ± 17.2	28 ± 22.1	16.5 ± 15	
Index hospitalization costs (€)	19,158 ± 10,089	23,718 ± 13,222	11,431 ± 9394	8715 ± 7640	

Trochu et al. Arch Cardiovasc Dis 2015

#### How has MitraClip helped?

#### 20,000 patients treated worldwide


## Mitraclip: patients, procedural times and outcomes




Registry (Ref. #)	N	Mean Age (yrs)	Male	Mean or Median Risk	NYHA Functional Class III/IV	Mean LVEF	FMR Etiology	≤2+ MR Post	Multiple Clips	Procedural Success*
		-			-					
TRAMI (90)	1,064	75	62%	10%†	87%	+	71%	96%	1.5 mean	95%
ACCESS-EU (91)	567	78	64%	23% <mark>§</mark>	85%		77%	91%	40%	99.6%
European Sentinel (92)	628	74	63%	20%§	86%	43%	72%	98%	37%	95%
EVEREST II and REALISM (93)	351	76	61%	11%†	85%	48%	70%	86%	39%	_
GRASP (94)	171	71	62%	7%†	81%	37%	78%	93%	41%	99%
MARS (95)	142	71	64%	17%§	68%	47%	54%	77%	47%	94%
Taramasso et al. (96)	109	69	84%	22%§	82%	28%	100%	87%	65%	99%
MitraSwiss (97)	100	77	67%	17%§	82%	48%	62%	85%	40%	85%
French multicenter (98)	62	73	72%	19% <mark>§</mark>	81%	40%	74%	88%	17%	95%
Treede et al. (99)	202	75	63%	44%§	98%	44%	65%	92%	35%	92%
Bozdag-Turan et al. (100)	121	77	69%	11%†	96%	42%	59%	99%	28%	97%
Rudolph et al. (101)	104	74	62%	36%§	100%	43%	66%	92%	38%	92%
Braun et al. (102)	119	71	67%	28%§¶	86%	35%‡	35%¶	-	-	86%
Neuss et al. (103)	157	74	67%	22% <mark>§</mark>	100%	41%	73%	100%	16%	98%

#### **Predominantly FMR**

#### Sustained reduction in MR grade





#### Sustained improvement in NYHA functional class



All cause mortality


Freedom from reoperation





#### EVEREST II + REALISM N=801, 52% DMR


Paul A. Grayburn et al. Circulation. 2013;128:1667-1674



#### Percutaneous treatment of MR as bail-out therapy for non-responders to CRT PERMIT-CARE




#### N = 51



P<0.001

12M


MR 4



Auricchio et al. J Am Coll Cardiol 2011


# Percutaneous treatment of MR as bail-out therapy for non-responders to CRT

$\textbf{172.1} \pm \textbf{82.9}$
$\textbf{102.8} \pm \textbf{62.9}$
$\textbf{31.6} \pm \textbf{18.1}$
25 (49)
35 (67)
7 (14)
1 (2)
5 (10)
1 (2)
1 (2)




#### Auricchio et al. J Am Coll Cardiol 2011

# Percutaneous treatment of MR as bail-out therapy for non-responders to CRT



Auricchio et al. J Am Coll Cardiol 2011; Maisano et al. J Am Coll Cardiol 2013


#### FMR vs. DMR SENTINEL PILOT study N=628, 72% FMR




#### All-cause mortality

HF rehospitalization


#### FMR vs. DMR SENTINEL PILOT study



#### FMR vs. DMR SENTINEL PILOT study




#### FMR vs. DMR SENTINEL PILOT study



#### Decreased burden of cost to the HealthCare system

#### Short length of stay<sup>1,2&3</sup>



Stay of patients after termination of mitral valve therapy in different age groups of patients (A & B)

1. C.Di Mario (Eurointervention 2012) 2. T. Feldman, et al., The New England journal of medicine 364, 1395 (2011) 3. S. Kar, et al., Journal of the American College of Cardiology 61, E1959 (2013) 4. M Gillard (NEJM 2012) 5. J. Wiebe, et al., Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2014).

#### Decreased burden of cost to the HealthCare system

- Cost-effectiveness study: EVEREST II HRS
  - MitraClip therapy to have a 92% chance of being cost-effective compared with standard of care at a willingness-to-pay threshold of \$50,000 per QALY gained.

#### On going trials

	СОАРТ	RESHAPE-HF	MITRA-FR
Number of patients and sites	430 patients at 75 U.S. and Canadian sites	800 patients at 50 E.U. sites	288 patients at 18 French sites
Secondary MR grade (core laboratory verified)	$\geq$ 3+ (EROA $\geq$ 30 mm <sup>2</sup> and/or Rvol >45 ml)	$\geq$ 3+ (EROA $\geq$ 30 mm <sup>2</sup> and/or Rvol >45 ml)	Severe (EROA >20 mm <sup>2</sup> + Rvol >30 ml)
NYHA functional class	II, III, or ambulatory IV	III or ambulatory IV	II-IV
LVEF	≥20% to ≤50%	$\geq$ 15% to $\leq$ 40%	≥15% to ≤40%
Surgical criteria	Not appropriate for mitral valve surgery (heart team)	None	None
Left ventricular volume entry criterion	LV end-systolic dimension $\leq$ 70 mm	LV end-diastolic dimension ≥55 mm	None
Control arm	Guideline-directed medical therapy (+CRT, if indicated)	Guideline-directed medical therapy (+CRT, if indicated)	Guideline-directed medical therapy (+CRT, if indicated)
Primary efficacy endpoint (superiority)	Heart failure rehospitalizations at 1 yr	Death or heart failure hospitalization at 1 yr	Death or recurrent heart failure hospitalization at 1 yr
Primary safety endpoint (noninferiority)	The composite of: SLDA; device embolization; endocarditis requiring surgery; echocardiography core laboratory-confirmed mitral stenosis requiring surgery; LVAD implant; heart transplant; or any device-related complications requiring nonelective cardiovascular surgery at 12 months	None	None
Health economics	Assessed	Assessed	None
Follow-up, yrs	5	2	2

Asgar et al. JACC 2015

## Conclusions

- MitraClip is a feasible and safe therapy for selected patients with significant MR
- Induces significant improvements in clinical symptoms and LV dimensions
- May be associated with reduced costs (compared with surgical and medical treatment)
- Future studies will help to establish the role of this therapy in selected subgroups of patients